A Study in Adults With Desmoid Tumors
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.
1) Histologically confirmed desmoid tumor. [+7]
1)Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β. [+8]